Bissonnette R, Bolduc C, Seité S, Nigen S, Provost N, Maari C, Rougier A
Innovaderm Research, Montreal, Canada.
J Cosmet Dermatol. 2009 Mar;8(1):19-23. doi: 10.1111/j.1473-2165.2009.00418.x.
New topical treatments for acne vulgaris are needed for patients who have tolerance problems with current treatments.
To compare the efficacy and tolerance of a lipophillic derivative of salicylic acid (lipo hydroxy acid or LHA) containing formulation and 5% benzoyl peroxide in subjects with acne vulgaris.
Eighty subjects with mild to moderate facial acne were randomized to receive either the LHA formulation twice a day or benzoyl peroxide once a day for 12 weeks. Efficacy and tolerance were evaluated at days 0, 28, 56 and 87. Results LHA formulation and benzoyl peroxide decreased the number of inflammatory lesions from baseline to week 12 by 44% and 47% and noninflammatory lesions by 19% and 23%, respectively. There was no statistically significant difference between the two treatments (P = 0.748; P = 0.445).
These results suggest that the LHA formulation could be a treatment option to consider in mild to moderate acne vulgaris patients that are intolerant to benzoyl peroxide.
对于对现有治疗有耐受性问题的寻常痤疮患者，需要新的局部治疗方法。
比较含亲脂性水杨酸衍生物（脂羟基酸或LHA）制剂与5%过氧化苯甲酰对寻常痤疮患者的疗效和耐受性。
80名轻度至中度面部痤疮患者被随机分为两组，一组每天使用LHA制剂两次，另一组每天使用一次过氧化苯甲酰，为期12周。在第0、28、56和87天评估疗效和耐受性。结果：LHA制剂和过氧化苯甲酰使炎症性皮损数量从基线到第12周分别减少了44%和47%，非炎症性皮损分别减少了19%和23%。两种治疗方法之间无统计学显著差异（P = 0.748；P = 0.445）。
这些结果表明，对于不耐受过氧化苯甲酰的轻度至中度寻常痤疮患者，LHA制剂可能是一种可考虑的治疗选择。
